$149.99
Research Studies:
FREE Shipping on
orders over $200
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are intended solely for research and laboratory use. These products are not intended for human or animal consumption. They are not medicines or drugs and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Any form of bodily introduction is strictly prohibited by law.
Survodutide 10mg is a research-use-only laboratory material supplied for controlled research workflows, compound characterization, and analytical documentation review. It is manufactured under rigorous quality standards to support consistency, traceability, and batch-specific verification for qualified laboratory settings.
Survodutide 10mg is intended strictly for laboratory research use only. This product is not intended for human or animal consumption, therapeutic use, diagnostic use, clinical use, veterinary use, or as a food, drug, cosmetic, dietary supplement, or household product.
| CAS No. | 2805997-46-8 |
|---|---|
| Sequence | H-Ac4c-QGTFTSDYSKYLDERAAKDFI-X-WLESA-NH2 where X = diacid-C18-γ-Glu-Gly-Ser-Gly-Ser-Gly-Gly-Lys |
| Molecular Formula | C192H289N47O61 |
| Purity | ≥99% |
| Molecular Weight | 4231.7 g/mol |
| Applications | Metabolic research, obesity studies, type 2 diabetes research, liver health investigations |
| Synthesis | Solid-phase synthesis |
| Solubility | Soluble in water or 1% acetic acid |
| Stability & Storage | Stable for up to 24 months at -20°C. After reconstitution, may be stored at 4°C for up to 4 weeks or at -20°C for up to 6 months. |
| Appearance | White lyophilized powder |
| Shipping Conditions | Shipped at ambient temperature; once received, store at -20°C |
| Regulatory/Compliance | Manufactured in a facility that adheres to cGMP guidelines |
| Safety Information | Refer to provided MSDS |
Consider these supplementary peptides for a comprehensive research approach.
For laboratory teams evaluating where to buy Survodutide for research, the safest product-page question is whether the RUO listing, COA, identity data, and lot documentation are clear before procurement review. Survodutide, also cataloged as BI 456906, is listed by PubChem and IUPHAR/BPS as a peptide research compound connected to glucagon and GLP-1 receptor pharmacology [1] [2]. This guide keeps the page focused on research documentation, analytical testing, literature interpretation, and claim boundaries for Pure Lab Peptides.
Researchers evaluating where to buy Survodutide for research should prioritize a batch-specific COA, clear RUO labeling, identity-confirming analytical data, lot traceability, and supplier documentation before procurement review. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. Published literature should guide context, not product claims.
The commercial phrase “buy Survodutide” becomes RUO-safe only when it is framed as buy Survodutide for research. That means the page should answer procurement and documentation questions, not outcome-driven questions.
A research buyer is looking for a clear product listing, a certificate of analysis, identity confirmation, purity data, lot matching, and research-use-only language. The safest page architecture keeps those items visible before any pathway discussion.
The first documents to review are the product label, COA, lot identifier, purity method, identity method, and any supplier notes tied to the exact batch. Official analytical guidance treats identity, purity, and related measurements as distinct analytical aims, which supports separating each data type in documentation review [16].
For peptide research materials, a COA should not be read as a generic marketing asset. It should connect the labeled Survodutide peptide material to the batch, the test method, the date, and the reported analytical data.
RUO labeling tells research buyers how the product page is positioned. It narrows the page to laboratory research, analytical review, and documentation, and it keeps the commercial page separate from personal or clinical contexts.
For Pure Lab Peptides, RUO language should be plain and repeated where it matters: product listing, documentation notes, COA access points, and procurement copy. Clear labeling reduces ambiguity.
Survodutide is indexed as a peptide compound with the molecular formula C192H289N47O61 and a PubChem molecular weight entry of about 4232 g/mol [1]. IUPHAR/BPS identifies Survodutide as a peptide and lists BI 456906 and BI456906 as synonyms [2].
Published literature describes BI 456906 as a GCGR/GLP-1R dual agonist peptide in discovery and preclinical pharmacology research [4]. A separate review describes Survodutide as a 29-amino-acid peptide derived from glucagon with GLP-1 activity incorporated into its design [5].
That identity framing is useful for a research product page because it connects the listing to literature, database records, and receptor context. It should not be used to imply a product claim.
BI 456906 is a key synonym for Survodutide in IUPHAR/BPS and PubChem records [1] [2]. A product page should include the synonym where it improves cross-reference clarity for researchers reviewing literature and database records.
ChEMBL also provides a compound record for Survodutide, which can help technical teams compare database naming, target annotation, and compound identifiers across sources [3]. When records agree on naming, procurement review becomes easier.
The 29-amino-acid peptide and C18 fatty acid details belong in the compound identity section because they help researchers understand why Survodutide is discussed as an acylated peptide [2] [5]. IUPHAR/BPS notes that the C18 fatty acid conjugate is associated with albumin-binding context and half-life discussion in the literature [2].
Published discovery literature also describes BI 456906 as an acylated peptide with a C18 fatty acid principle [4]. On an RUO page, that detail supports identity and literature mapping only.
A Survodutide peptide product page should make the research lane clear. The page should describe the compound, the documentation package, the analytical review points, and the limitations of published literature.
Product listings should state that the material is intended for research purposes and should avoid claims that point outside laboratory research. The listing should also make the compound name, synonym, physical form, lot documentation, and COA path easy to review.
A listing that uses Survodutide, BI 456906, and research peptide language in a controlled way can serve commercial research intent without drifting into unsafe product positioning.
A clear research compound listing aligns the product name, synonym, catalog description, COA, lot number, and vial label. It also avoids turning receptor pathway context into claims.
For technical procurement teams, clarity means fewer gaps between the product page and the batch documentation. The label, COA, and supplier records should tell the same story.
Online listings support buy Survodutide for research intent when they answer research procurement questions directly. A useful listing should show what documentation is available and what analytical methods support the material description.
The safest commercial framing is documentation-first. Researchers can then evaluate whether the product listing, COA, and lot-level records fit their laboratory research requirements.
Survodutide belongs in a metabolic pathway research lane because the literature connects it to GLP-1R and GCGR receptor models [2] [4]. UniProt identifies GLP1R as the glucagon-like peptide-1 receptor entry and GCGR as the glucagon receptor entry [7] [8].
The metabolic research lane centers on receptor signaling, pathway models, and compound characterization. IUPHAR/BPS places GLP-1R and GCGR within the glucagon receptor family, which supports same-lane receptor context [9] [10].
This framing is safer than consumer outcome language. It keeps the product page focused on receptor research and documentation review.
Same-lane receptor context helps readers understand why GLP-1, glucagon receptor, GLP-1R, and GCGR appear on a Survodutide research page. De Graaf and colleagues describe GLP-1R as a class B G protein-coupled receptor that mediates GLP-1 peptide signaling [11].
For product-page SEO, same-lane context improves topical relevance. For RUO compliance, it keeps that relevance tied to literature and receptor classification.
Survodutide functions as a dual agonist in GCGR and GLP-1R research literature [2] [4]. That statement should be handled as receptor pharmacology context, not as a product-page promise.
GLP-1R and GCGR are both class B receptor targets in the glucagon receptor family [9] [10]. Structural and pharmacology literature has investigated how peptide ligands interact with these receptor systems [11] [12].
The research model connection is useful for literature interpretation. It does not change the RUO status of the material.
Dual agonist language means the literature discusses activity at two receptor targets rather than one. IUPHAR/BPS describes Survodutide as a glucagon/GLP-1 receptor dual agonist, and the discovery literature describes GCGR/GLP-1R research characterization [2] [4].
In a product page, the term should remain tied to source interpretation. It should not be expanded into claims about outcomes.
A pathway can be relevant to research without becoming a claim about a material listing. The difference is intent.
A research page can say that literature examines GLP-1R, GCGR, receptor signaling, and peptide structure. It should not state or imply that an RUO material produces a specific outcome outside controlled research settings.
The evidence landscape for Survodutide includes database identity records, receptor-target resources, structural receptor literature, preclinical pharmacology literature, and human study literature outside RUO product use. Some published literature outside the scope of RUO product use has examined this compound class in human study settings. That literature should not be interpreted as a use claim for research-use-only materials [6].
| Research Area | What Literature Examines | Evidence Type | RUO Interpretation |
|---|---|---|---|
| Compound identity | Survodutide synonyms, formula, class, and database records [1] [2] [3] | Official database | Supports identity review, not product claims |
| Receptor context | GLP-1R, GCGR, and glucagon receptor family annotations [7] [8] [9] [10] | Database and receptor guide | Supports pathway mapping |
| Preclinical pharmacology | BI 456906 receptor and pathway research [4] | Published preclinical literature | Supports model-specific context only |
| Structural receptor science | GLP-1R and GCGR structural research [11] [12] [13] [14] [15] | Structural biology | Supports receptor interpretation |
| Analytical documentation | Method validation, peptide identity, and purity testing principles [16] [17] [18] | Official guidance and analytical literature | Supports COA and testing review |
Preclinical literature can support compound background, receptor model context, and mechanistic questions that researchers may investigate. Zimmermann and colleagues describe BI 456906 in GCGR/GLP-1R discovery and preclinical pharmacology research [4].
Preclinical findings should stay in their model-specific context. They should not be converted into product-page claims for Pure Lab Peptides materials.
Assay metrics belong to the conditions of the assay. Receptor activity values, cell-line context, experimental design, and analytical methods all affect how the data should be read [4].
For Survodutide research, receptor assay findings can help explain why GCGR and GLP-1R appear in the literature map. They should not be used as a shortcut for product claims.
Translational limits should appear wherever a page moves from literature summary to product documentation. This is especially important when a compound has literature across multiple evidence categories.
A safe article separates three things: what the literature examines, what the product documentation confirms, and what the RUO page does not claim. That separation keeps the product page focused.
The key research boundary is simple. Published literature can inform compound context, but product-page copy should focus on identity, purity, COA review, lot traceability, and RUO labeling.
A published paper may examine receptor activity, pathway signaling, structure, or model-specific pharmacology. A product page should not transform those findings into claims about the material.
For Survodutide, the safe approach is to cite literature for scientific background and then return to documentation. That means COA review, analytical testing, and lot matching remain the commercial research focus.
Claim boundaries define what the page can say and what it should avoid. Phrases that sound consumer-facing or outcome-oriented can blur the distinction between literature context and product positioning.
RUO pages should emphasize documentation. That includes compound identity, batch-specific COA review, analytical verification, and supplier records.
A COA is a batch-specific documentation tool. It should help a research buyer check whether the reported Survodutide material aligns with the product label and lot record.
A certificate of analysis matters because it organizes test information in a way that can be reviewed before procurement. Official analytical guidance describes identity, purity, and assay-type measurements as separate analytical aims [16] [18].
For Survodutide peptide materials, the COA should support the product page rather than replace it. The product page explains the research listing; the COA should provide batch-level data.
Useful COA fields include compound name, synonym, lot identifier, purity value, analytical method, date, lab source, and any available chromatogram or mass data. ISO/IEC 17025 describes a framework for competent testing and calibration laboratories, which is relevant when assessing the credibility of laboratory reporting [24].
FDA laboratory guidance also emphasizes that laboratory reports and certificates should reflect documented data review rather than selective reporting [30]. That principle supports careful COA review.
A COA date should make sense next to the lot identifier and product record. If the COA, label, and supplier record do not align, the buyer should resolve that documentation gap before procurement.
Traceability is a documentation concept. NIST describes metrological traceability as a property of measurement data supported by a documented chain of comparisons [25].
Purity and identity are related, but they are not the same. A purity value helps describe the proportion of the target material relative to detectable impurities under a stated method, while identity testing supports whether the material matches the intended peptide.
HPLC can support peptide purity review by separating components under defined chromatographic conditions. USP peptide mapping material describes chromatographic separation as part of identity-focused peptide mapping for proteins and related materials [19].
For a Survodutide COA, the key question is whether the method is named and whether the reported data are tied to the batch. Purity data without method context are less useful.
LC-MS can support peptide identity review because it combines chromatographic separation with mass spectrometric information. Lian and colleagues describe LC-MS as a central tool for characterizing synthetic peptide impurities and structural features [20].
Prabhala and colleagues also describe mass spectrometry as well suited for analysis of synthetic peptide identity and purity [21]. For research procurement, that supports asking whether identity data are available.
Mass spectrometry adds mass-based evidence. It can help compare observed mass data with expected molecular identity when paired with appropriate method details and reference information [21].
LC-HRMS literature also describes peptide characterization workflows that can identify peptide-related impurities and support qualitative analysis [23]. This is documentation support, not a replacement for batch-specific review.
A numbered lab-test verification workflow keeps the review documentation-focused:
These steps stay within documentation review. They do not provide product-use guidance.
Retention time belongs to chromatographic method context. Mass data belong to molecular identity context.
Wei and colleagues describe liquid chromatography peptide mapping with mass spectrometric detection as an identity and characterization tool [22]. In a COA review, the practical question is whether those data connect clearly to the Survodutide lot.
Reference standards improve documentation review by providing a comparison point for measurements. NIST notes that standard reference materials are certified and supplied with well-characterized composition or properties [26].
For research-grade Survodutide documentation, reference information can improve confidence in the analytical record. It should still be assessed alongside the COA, lot number, method, and supplier documentation.
Lot traceability connects a physical research material to its documentation. Vial labeling connects the material container to the same identity record.
Lot numbers matter because they link the labeled material to the COA and supplier documentation. Without lot-level alignment, a COA may not prove that it belongs to the material being reviewed.
ISO/IEC 17025 and NIST traceability concepts both support the broader principle that laboratory documentation should allow data to be tied back to the measurement and material context [24] [25]. For procurement teams, that means matching the lot across records.
A peptide vial label should align with the product name, lot identifier, and COA. It should also avoid unsupported claim language.
The best review question is simple: does the label match the documentation? If the answer is unclear, the documentation package needs closer review before the material is selected for laboratory research.
Storage documentation should describe how the material should be maintained in a laboratory inventory setting. It should not become preparation or application guidance.
Storage notes should clarify temperature category, light exposure considerations, moisture protection, and recordkeeping expectations. Peptide stability literature describes sequence, formulation, and storage context as factors that can affect peptide integrity [27].
The product page should not overstate stability. It should tell lab teams where to find storage documentation and how that documentation connects to the labeled material.
Lyophilized peptide documentation supports chain-of-custody review by giving a stable record of material identity, storage category, and handling notes. A comparative peptide storage study found that storage conditions can influence peptide degradation patterns over time, which reinforces the need for documentation rather than assumptions [28].
The National Academies’ laboratory chemical management guidance also emphasizes chemical inventory, tracking, and storage management as core laboratory practices [29]. Those practices fit RUO peptide recordkeeping.
A procurement checklist helps keep commercial research intent focused on verification. It gives technical buyers a repeatable way to evaluate research-grade Survodutide documentation.
Research buyers should compare documentation depth rather than marketing language. Useful comparison points include COA availability, analytical method naming, lot traceability, vial labeling, and RUO clarity.
The strongest supplier documentation is specific. It ties the Survodutide research material to a batch, method, and record set.
Research-grade Survodutide documentation supports evaluation by reducing uncertainty. It does not replace independent review by qualified research teams.
A strong documentation package makes it easier to compare identity records, COA data, and supplier notes. This is the practical center of buy Survodutide for research intent.
Supplier records support product-page confidence when they are consistent, current, and batch-specific. The product page should make it clear what documentation is available and how researchers can review it.
Confidence should come from traceability and analytical support. It should not come from claims that move beyond laboratory research.
The final review should bring together identity, literature context, COA data, analytical methods, labeling, lot traceability, and RUO positioning. This section is where common misunderstandings should be cleared before the page moves into final editorial review.
The final review should confirm that Survodutide and BI 456906 are used consistently, that the COA matches the lot, that purity and identity testing are documented, and that the product page stays within research-use-only boundaries.
Common misunderstandings to avoid:
Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.
Review the product-page documentation, COA details, analytical testing notes, and RUO labeling before evaluating Survodutide for laboratory research.
Survodutide is a research peptide discussed in receptor-focused literature and database records as BI 456906 [2]. In a product-page context, that identity supports documentation review, not product claims. Researchers should compare the compound name, synonym, molar mass, COA details, and batch records before they buy Survodutide for research.
BI 456906 is a synonym used in Survodutide research literature and scientific database records [2]. The term helps researchers cross-check product documentation against published literature, receptor resources, and compound records. A clear COA should align the Survodutide name, BI 456906 reference, peptide identity data, and lot-specific documentation.
Researchers evaluate Survodutide as a receptor agonist by reviewing model-specific literature, receptor annotations, and analytical documentation. Published sources describe Survodutide in GLP-1R and GCGR research contexts [2] [4]. Product pages should keep that receptor discussion tied to compound characterization, pathway models, COA review, and literature interpretation.
Signaling pathways provide a research framework for interpreting Survodutide literature. GLP-1R and GCGR context can help researchers understand why dual receptor models appear in published work [4]. For RUO product pages, pathway discussion should remain separate from product claims and should point back to research documentation and analytical testing.
In vitro or EC50 data should be interpreted as model-specific research information. These values depend on assay design, receptor system, and experimental conditions, so they should not be treated as general product-positioning language. For product-page review, researchers should connect literature data to compound identity, COA records, peptide content, and method transparency.
Form-related documentation should clarify whether the Survodutide material is presented as peptide powder and how the label, COA, and supplier record describe the batch. High-purity Survodutide language should be supported by analytical testing rather than marketing phrasing. Researchers should review HPLC, LC-MS, lot traceability, and peptide identity documentation together.
The following authors are recognized for published research that helped shape the scientific context discussed in this article.
Author profile: ResearchGate
Tina Zimmermann is a published research author whose work is directly relevant to Survodutide, BI 456906, GCGR, and GLP-1R literature. Her publications provide useful context for interpreting Survodutide as a research peptide within metabolic pathway research and receptor pathway research. The selected work below is especially relevant to compound characterization, preclinical literature review, receptor-focused study design, and model-specific interpretation. This recognition is based on her published research contributions to the scientific background discussed in the article.
Selected publications:
Author profile: ORCID
Dieter Hamprecht is a published author associated with Survodutide and GLP-1/glucagon receptor research literature. His selected publications are relevant to the article’s discussion of BI 456906, peptide structure, receptor pharmacology, in vitro characterization, and pathway-focused research interpretation. This work helps support a research-context explanation of how Survodutide appears in the published literature while keeping product-page discussion centered on documentation, compound identity, and analytical review.
Selected publications:
This research disclaimer clarifies how this page handles published literature and search language around Survodutide in metabolic pathway and incretin receptor research. Phrases such as “buy Survodutide online,” “Survodutide peptide for sale,” “high-quality Survodutide,” “investigational peptide,” “Survodutide for obesity,” and “bodyweight reduction of Survodutide” can drift into consumer-facing, clinical-use, wellness, or product-claim language when separated from research context. On this page, those phrases are treated only as language-boundary examples tied to published literature interpretation and product documentation review.
Terms such as “Survodutide treatment,” “energy expenditure,” “product effects,” “product performance,” “clinical outcomes,” “wellness language,” “disease,” and “potency” require the same careful separation from product positioning. The focus remains on Survodutide identity, COA review, analytical testing, peptide purity, lot traceability, RUO labeling, product documentation, and model-specific literature boundaries. Research-use-only content should support qualified laboratory evaluation without turning pathway or study terminology into product claims, intended applications, personal-use guidance, or outcome-oriented positioning.
Our team is ready to assist you with any inquiries regarding our catalogue of peptides and their applications.
Discount Applied Successfully!
Your savings have been added to the cart.
There are no reviews yet.